Unlock proteomics for drug discovery
Download our eBook to learn how proteomic biomarkers can accelerate drug discovery and development, reducing risks from target identification to clinical trial research.
Comparison
How Olink proteomics supports drug discovery and development
Olink solutions help pharma and biotech research teams generate high-quality protein biomarker evidence across all stages of the drug development pipeline. With high-specificity technology, scalable discovery-to-focused panel options, and expert support, you can investigate disease biology, population heterogeneity, treatment-associated biology, and safety signals with greater confidence.
Olink proteomics-enabled approach
Traditional approach
Target discovery
Discovers high-specificity proteomic signatures to identify causal biology and support relevant target hypotheses
Often limited to genomics or transcriptomics insights only, which don’t always translate directly to dynamic disease states
Cohort strategies
Can discover proteomic signatures associated with likely responders, helping reduce study size
Typically use broad clinical research criteria for guiding enrollment
Mode of action
Measure on- and off-target protein changes to characterize drug mechanisms
Rely on limited biomarkers to infer mode of action
Longitudinal research
Support longitudinal studies in accessible, non-invasive biopsies and small sample volume requirements, as little as 1 µL
Use invasive biopsies and/or expensive imaging that limit sample collection
Repurposing
Allows systematic identification of new indications through large-scale proteomic profiling of thousands of targets
Often depends on opportunistic discoveries or limited cross-disease biological evidence
Use cases
Explore proteomic applications in pharma research
Dive deeper into how Olink proteomics accelerates key applications in the drug development process, from early target discovery to translational and clinical trial research.
Expert perspective
Expert perspective: Population-scale proteomics for target discovery
Dr. Chris Whelan, former Chair and Principal Investigator of the UK Biobank Pharma Proteomics Project (UKB-PPP), discusses how the UKB-PPP pilot is profiling ~50,000 samples with Olink Explore to connect genetic variation and protein levels, enabling the identification of causal disease biomarkers and higher-confidence drug targets.
Learning resources
Resources for proteomics-enabled drug development
Explore resources showing how you can integrate Olink proteomics into your drug development program.
Expert perspective
Advancing disease understanding and therapy development
Dr. Ryan Dhindsa, PhD, Professor at Baylor College of Medicine, discusses leveraging phenome-wide association studies, exome-wide association studies), and collapsing analysis to aid in the identification of new therapeutic targets and potential clinical biomarkers.
Testimonials
Voices of our customers
Real perspectives from researchers using Olink solutions to improve biomarker discovery, translational research, and proteomics analysis.
Research highlights
Selected reading in drug development
Explore case studies and articles showing how Olink solutions accelerate drug discovery, facilitate every stage of drug development, and help reduce pipeline risks.
